IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
This study has been withdrawn prior to enrollment.
(Study closed by Protocol Review Monitoring Committee because of lack of accrual)
Sponsor:
University of Kansas
Collaborator:
Novartis
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas )
ClinicalTrials.gov Identifier:
NCT01163929
First received: July 14, 2010
Last updated: October 22, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
| Study Status: | This study has been withdrawn prior to enrollment. |
|---|---|
| Study Completion Date: | March 2012 |
| Primary Completion Date: | March 2012 (Final data collection date for primary outcome measure) |